SEC Form 4 · accession 0001209191-15-085462
Anacor Pharmaceuticals, Inc. · ANAC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul L Berns
Officer — President and CEO · Director
Period of report
Dec 11, 2015
Accepted (ET)
Dec 15, 2015 · 9:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411158
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 11, 2015 | M | 14,000 | $5.20 | A | 268,760 | D | |
| Common Stock | Dec 11, 2015 | M | 6,000 | $21.21 | A | 274,760 | D | |
| Common StockF2,F3 | Dec 11, 2015 | S | 590 | $115.5243 | D | 274,170 | D | |
| Common StockF2,F4 | Dec 11, 2015 | S | 10,732 | $117.0378 | D | 263,438 | D | |
| Common StockF2,F5 | Dec 11, 2015 | S | 8,178 | $117.6014 | D | 255,260 | D | |
| Common StockF2,F6 | Dec 11, 2015 | S | 500 | $118.5873 | D | 254,760 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F7 | $5.20 | Dec 11, 2015 | M | 14,000 | D | — | May 30, 2022 | Common Stock | 14,000 | 0 | D |
| Stock Option (right to buy)F8 | $21.21 | Dec 11, 2015 | M | 6,000 | D | — | Mar 21, 2024 | Common Stock | 6,000 | 294,000 | D |
Explanation of responses
- F1This sale was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person for tax and estate planning purposes.
- F2The price reported in Column 4 is a weighted average price.
- F3These shares were sold in multiple transactions at prices ranging from $115.24 to $115.75, inclusive.
- F4These shares were sold in multiple transactions at prices ranging from $116.25 to $117.24, inclusive.
- F5These shares were sold in multiple transactions at prices ranging from $117.25 to $118.20, inclusive.
- F6These shares were sold in multiple transactions at prices ranging from $118.36 to $118.87, inclusive.
- F7This option is fully vested and exercisable.
- F8The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting each month thereafter. The Vesting Commencement Date was March 18, 2014.